Corcept Therapeutics Inc (CORT)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$72.50

Buy

$74.24

arrow-up$1.29 (+1.80%)

Prices updated at 02 May 2025, 23:55 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
NASDAQ
arrow-up1.51%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. James N. Wilson
CEO
Dr. Joseph K. Belanoff, M.D.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
500
Head office
101 Redwood Shores Parkway
Redwood City
United States
94065
mobile
+1 650 327-3270
letter
ir@corcept.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. David L. Mahoney
Independent Director
0.08m
Mr. Daniel N. Swisher,Jr
Independent Director
0.06m
Mr. George Leonard Baker, Jr
Independent Director
0.07m
Dr. Gregg H. Alton, J.D.
Independent Director
0.09m
Dr. Joseph K. Belanoff, M.D.
Director, President and Chief Executive Officer
1.14m
Mr. James N. Wilson
Chairman of the Board
0.13m
Mr. G. Charles Robb
Chief Business Officer and Secretary
0.69m
Mr. Atabak Mokari
Chief Financial Officer and Treasurer
0.55m
Mr. Sean Maduck
President, Corcept Endocrinology
0.63m
Ms. Kimberly Park
Independent Director
0.06m
Mr. Joseph Douglas Lyon
Chief Accounting Officer and Chief Technology Officer
-
Dr. Hazel Hunt, PhD
Chief Scientific Officer
-
Dr. Gillian M. Cannon, PhD
Independent Director
0.07m
Mr. Joshua M. Murray
Independent Director
0.06m
Dr. William Guyer, Pharm.D.
Chief Development Officer
0.66m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock Inc15,677,327
Vanguard Group Inc10,115,624
BlackRock Fund Advisors9,781,476
Ingalls & Snyder LLC8,099,747
Renaissance Technologies Corp6,198,602

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
06 Jul 2022-
31 Jul 2024-
31 Jul 2024-
06 Jul 2022-
27 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
02 Dec 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.